In the latest session, Capricor Therapeutics Inc (NASDAQ: CAPR) closed at $6.38 down -7.27% from its previous closing price of $6.88. In other words, the price has decreased by -$0.50 from its previous closing price. On the day, 740562 shares were traded.
Ratios:
For a deeper understanding of Capricor Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.63 and its Current Ratio is at 1.63. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on January 05, 2024, initiated with a Overweight rating and assigned the stock a target price of $8.
On October 26, 2022, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $15.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 12 ’23 when Musket David B bought 410 shares for $2.75 per share. The transaction valued at 1,128 led to the insider holds 31,536 shares of the business.
COLLIER EARL M JR bought 10,000 shares of CAPR for $28,300 on Oct 10 ’23. The Director now owns 26,856 shares after completing the transaction at $2.83 per share. On Oct 09 ’23, another insider, Musket David B, who serves as the Director of the company, bought 5,083 shares for $2.82 each. As a result, the insider paid 14,334 and bolstered with 31,126 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAPR now has a Market Capitalization of 200.33M and an Enterprise Value of 163.08M. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.96 while its Price-to-Book (P/B) ratio in mrq is 8.79. Its current Enterprise Value per Revenue stands at 6.48 whereas that against EBITDA is -7.09.
Stock Price History:
Over the past 52 weeks, CAPR has reached a high of $8.22, while it has fallen to a 52-week low of $2.68. The 50-Day Moving Average of the stock is 4.63, while the 200-Day Moving Average is calculated to be 4.55.
Shares Statistics:
For the past three months, CAPR has traded an average of 264.73K shares per day and 492.46k over the past ten days. A total of 31.15M shares are outstanding, with a floating share count of 28.64M. Insiders hold about 8.79% of the company’s shares, while institutions hold 12.80% stake in the company. Shares short for CAPR as of Feb 29, 2024 were 2.7M with a Short Ratio of 10.20, compared to 2.69M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.67% and a Short% of Float of 8.87%.
Earnings Estimates
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of $0.03 and a low estimate of -$0.26, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.26 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$0.75 and -$1.36 for the fiscal current year, implying an average EPS of -$0.96. EPS for the following year is $0.1, with 4 analysts recommending between $1.44 and -$1.21.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $9.7M this quarter.It ranges from a high estimate of $14.1M to a low estimate of $5M. As of the current estimate, Capricor Therapeutics Inc’s year-ago sales were $2.99M, an estimated increase of 224.80% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $4.41M, an increase of 12.60% less than the figure of $224.80% in the same quarter last year. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $3.92M.
A total of 3 analysts have provided revenue estimates for CAPR’s current fiscal year. The highest revenue estimate was $30M, while the lowest revenue estimate was $27.2M, resulting in an average revenue estimate of $28.53M. In the same quarter a year ago, actual revenue was $25.18M, up 13.30% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $119.36M in the next fiscal year. The high estimate is $185M and the low estimate is $22.5M. The average revenue growth estimate for next year is up 318.40% from the average revenue estimate for this year.
